Abstract
Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their microenvironment. Multiple myeloma is so far the most responsive malignancy.
Keywords: angiogenesis, antiangiogenesis, multiple myeloma, thalidomide
Letters in Drug Design & Discovery
Title: Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma
Volume: 1 Issue: 2
Author(s): Domenico Ribatti and Angelo Vacca
Affiliation:
Keywords: angiogenesis, antiangiogenesis, multiple myeloma, thalidomide
Abstract: Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their microenvironment. Multiple myeloma is so far the most responsive malignancy.
Export Options
About this article
Cite this article as:
Ribatti Domenico and Vacca Angelo, Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma, Letters in Drug Design & Discovery 2004; 1 (2) . https://dx.doi.org/10.2174/1570180043485491
DOI https://dx.doi.org/10.2174/1570180043485491 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics The Role of the Complex USP1/WDR48 in Differentiation and Proliferation Processes in Cancer Stem Cells
Current Stem Cell Research & Therapy Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Does Ligand Symmetry Play a Role in the Stabilization of DNA G-Quadruplex Host-Guest Complexes?
Current Medicinal Chemistry Multimodal Navigation in Glioma Surgery
Current Medical Imaging Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Current Cancer Therapy Reviews Dendrimers in Photodynamic Therapy
Current Medicinal Chemistry A Comprehensive Insight Towards Pharmaceutical Aspects of Graphene Nanosheets
Current Pharmaceutical Biotechnology Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging Meet Our Editorial Board Member
Current Neuropharmacology MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer
Current Molecular Medicine Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews